Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for Triple Negative Breast Cancer
184 locations incl. Birmingham
Sponsor: Gilead Sciences
Sex: All·Age: 18+
Code: NCT05633654·Phase 3·Recruiting